A Study to Determine the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of ABBV-927 With ABBV-368, Budigalimab (ABBV-181) and/or Chemotherapy in Participants With Locally Advanced or Metastatic Solid Tumors

NCT03893955 · clinicaltrials.gov ↗

PHASE1

Phase

ACTIVE_NOT_RECRUITING

Status

150

Enrollment

INDUSTRY

Sponsor class

Conditions

Cancer
Advanced Solid Tumors
Triple-Negative Breast Cancer (TNBC)
Non-small-cell-lung-cancer (NSCLC)
Metastatic Solid Tumors

Interventions

DRUG: ABBV-927
DRUG: ABBV-368
DRUG: ABBV-181
DRUG: Carboplatin
DRUG: Nab-paclitaxel

Sponsor

AbbVie